Instem Share Discussion Threads

[sharesoc] 31/10/2019 19:07

Instem present at our next Manchester seminar on the 19th November which may be of interest to potential investors and current shareholders. More details and registration here:

[lomax99] 28/10/2019 13:02

Thanks, happy to average down when the opportunity presents itself.

[p1nkfish] 28/10/2019 10:08

They are in a very sweet spot where a number of very lucrative drivers converge. Welcome. Best to average in on any weakness. Good luck.

[lomax99] 28/10/2019 09:53

Thanks for the PI world link. The 3-5 year revenue comment on £50 - £75m (both organic and acquisition) looks optimistic, with operational leverage increasing as they scale towards EBITDA margins of 25%. If they achieve the mid-point of that range, and achieve the anticipated margin expansion then the PE drops to c 4.

Just made an initial purchase, looking at the chart I feel a little late to the party, so will monitor before increasing too much.

[tomps2] 25/10/2019 14:23

Here's the Instem investor presentation by Phil Reason, CEO. Given at the piworld-Progressive Equity Research event in September. Phil was over for the H1 19 results, (normally he's in the US).

A very comprehensive overview of the different parts of the business, and a positive outlook.

[2niffy] 15/10/2019 14:22

Rights issue very unlikely. Management incentivised by share price. They own 16% ish of company at 102p.Rights issue dilutes them, loss of control.

[mw8156] 22/9/2019 19:35

strong market position in an expanding niche, but little liquidity and not much on the balance sheet, may well attract a bid following bids for sanderson, scisys and statpro? have to hope for good results tomorrow,

[p1nkfish] 19/9/2019 16:58

News on 17/9.
Neat, mentions the ML buzzword too.
Really like this company.

[mortimer7] 19/9/2019 16:23

A few buys yesterday, possible speculators ahead of results?

[p1nkfish] 13/9/2019 09:18

Results on 23rd and chance of a convincing move through £4.

[p1nkfish] 27/8/2019 12:56

Yes and would be a great shame.
A real picks and shovels play on bio-tech, saas & cloud. What a combo. Good margins and growth.

[equitydev] 27/8/2019 12:31

Instem highlighted (page 4) as a potential acquisition target in today's M&A related research report - UK plc ‘going for a song’.

hxxps://www.equitydevelopment.co.uk/2019/08/27/uk-plc-going-for-a-song/

[p1nkfish] 22/7/2019 13:02

Lovely and quiet and look at that price.

[p1nkfish] 15/7/2019 07:33

Very healthy TU.

A good way to take advantage of bio-tech without being exposed to front-line approval risk but taking advantage of that risk by helping make it easier to document.

Good on all product fronts at INS including AI mention.

[p1nkfish] 10/6/2019 15:17

Interesting Chineze news, 4/6/19 -

[mw8156] 18/4/2019 15:33

thanks P1nk for that link

[p1nkfish] 18/4/2019 14:59

Taken a long time for this action to occur.

[mw8156] 18/4/2019 14:15

as a lay person what does a first and second price monitoring mean and why is it necessary if only 28000 shares have been traded?
this company certainly has potential with its stranglehold on preclinical data software and blue chip client base.

[p1nkfish] 12/4/2019 16:29

They mentioned acquisitions too, being on look out, 6-12 months back.

[mw8156] 12/4/2019 15:11

Thanks for that insight, P1NK, hadn't occurred to me, but they did say something about wanting to get more into clinical trial data submission software at their small investor event, seem to recall,
rather alarmed that their NTAV is negative and they don't pay any divi so high-risk to that extent especially if a placing is in the offing.

[p1nkfish] 12/4/2019 14:49

No new shares issued, just a release of shares to spread holder base.

However, I do suspect this could signal a raising being in the offing for an acquisition. Having a wider shareholder base could help considerably if they want to raise a decent sum.

Hope they offer pi's a chance to take part if they raise.

Also, I think low hanging fruit of acquisitions are gone so size of acquisition likely to be larger and a wider shareholder base then needed, more/deeper pockets to help fund it.

Just imho. Dyor.

[wjccghcc] 11/4/2019 07:43

Placing by two of the founders. They are both non-execs and both look to be in their 70's so I guess it's a good thing in the long term.

[p1nkfish] 02/4/2019 11:13

Absolutely, less lumpy. Worth a premium for predictability.

[wjccghcc] 02/4/2019 09:52

Quite big upgrades from N+1 and Progressive. The thing I liked in the results was that the license revenue is down to 15% from 25% as the switch to SaaS increases. Gives more visibility of revenues.